Among several recognized cancer-related pathway drugs, low-risk scoring cases had significantly lower IC50s for KRAS (G12 C) inhibitor-12, JAK1_8709, Wnt-C59, and LY2109761, and higher sensitivity to AZ960 (Fig. 5D). The gene discussed is KRAS; the disease is cancer.